Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Treatment Strategies for Childs-Pugh B Disease

March 25th 2021

Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.

Frontline Trials for Unresectable HCC

March 25th 2021

Amit Singal, MD, MS, and Stephen L. Chan, MD, review the IMbrave150, LEAP-002, and CheckMate 9DW trials for unresectable hepatocellular carcinoma.

TACE-3 and CheckMate 74W Trials for BCLC stage B or stage C HCC

March 25th 2021

Stephen L. Chan, MD, reviews data from key trials of emerging combinations of TACE (transarterial chemoembolization), plus systemic therapies for BCLC (Barcelona Clinic Liver Cancer) stage B or C hepatocellular carcinoma.

Initial Strategies for Assessing and Treating mCRC

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.

Dr. Salem on Outcomes With Y-90 as Bridging Therapy Prior to Transplant in HCC

March 24th 2021

Riad Salem, MD, discusses outcomes with TheraSphere™ Yttrium-90 Glass Microsphere as a bridging therapy prior to transplantation in hepatocellular carcinoma.

Racial Disparities Persist in GI Cancers and Beyond

March 24th 2021

Racial disparities affecting all aspects of patient care are a major issue across cancer types, including for patients with gastrointestinal cancers.

Immunotherapy Makes Waves in Gastroesophageal and Gastric Cancers

March 24th 2021

Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.

Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies

March 23rd 2021

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

Dr. Salem on Selecting the Appropriate Treatment Approach in HCC

March 23rd 2021

Riad Salem, MD, discusses considerations for selecting the appropriate treatment approach for patients with hepatocellular carcinoma.

Dr. Choti on Challenging Treatment Decisions in NETs

March 23rd 2021

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

Pemigatinib Approved in Japan for Unresectable, FGFR+ Biliary Tract Cancer

March 23rd 2021

The Japanese Ministry of Health, Labour, and Welfare has approved pemigatinib for the treatment of patients with unresectable biliary tract cancer with a FGFR2 fusion gene, worsening following chemotherapy.

The Future of Biliary Tract Treatment Lies in Molecular Profiling

March 22nd 2021

Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, such as pemigatinib and ivosidenib in the advanced setting.

Dr. Basu-Mallick on the Importance of Clinical Research Examining ctDNA in CRC

March 22nd 2021

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.

FDA Approves Pembrolizumab for Advanced Esophageal or GEJ Cancer

March 22nd 2021

The FDA has approved pembrolizumab for use in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma who are ineligible for surgical resection or definitive chemoradiation.

TKIs Trump Immunotherapy Following Atezolizumab/Bevacizumab Treatment in HCC

March 22nd 2021

The combination of atezolizumab and bevacizumab is the clear frontline standard of care for patients with advanced hepatocellular carcinoma without contraindications.

Optimizing Adjuvant Therapy for Advanced Cholangiocarcinoma

March 22nd 2021

Insight regarding best timing to initiate an appropriate adjuvant therapy in patients with advanced cholangiocarcinoma, and the role of ctDNA analysis in the postsurgical setting.

Adjuvant Therapy for Advanced Cholangiocarcinoma

March 22nd 2021

Current treatment approaches for advanced cholangiocarcinoma, despite current gaps that can be considered in the adjuvant setting, as highlighted by GI oncologists.

NCCN Guidelines for Gastric and Esophageal Cancers Updates Encompass Immunotherapy, TKIs Across Settings

March 20th 2021

Key updates to the National Comprehensive Cancer Network guidelines for gastric and esophageal cancers include the incorporation of immune checkpoint inhibitors spanning settings in patients with gastroesophageal cancer, the inclusion of fam-trastuzumab deruxtecan-nxki for those with HER2-positive gastric cancer, and the addition of recommended ramucirumab combinations for use in second- or later-line settings.

HCC-TAG Conference to Highlight Headway Made in HCC Care Amidst COVID-19 Pandemic

March 19th 2021

Anjana Pillai, MD, discusses recent advances made in the HCC treatment paradigm, as well as what the conference will offer to healthcare providers working in the field.

Dr. Salem on the FDA Approval of Y-90 Glass Microspheres for HCC

March 18th 2021

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.